Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Association between Deaths Due to Infection and Mutations of the BRAF, FBXW7, NRAS and XPO1 genes: A Report from the LRF CLL4 Trial

Monica Else, MA,MSc, Stuart J Blakemore, PhD, Jonathan C Strefford, PhD, Daniel Catovsky, MD FRCP

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134544

Published: 2020

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Anton Parker, Ben Gregory, Zadie Davis, Monica Else, MA, MSc, Matthew JJ Rose-Zerilli, PhD, Jonathan C Strefford, Daniel Catovsky, MD, DSc(Med), David Oscier

Blood (2013) 122 (21): 4137.

https://doi.org/10.1182/blood.V122.21.4137.4137

Published: 2013

Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes

Blood (2011) 118 (21): 4986.

https://doi.org/10.1182/blood.V118.21.4986.4986

Published: 2011

Journal Articles

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Sarah L Hockley, PhD, Monica Else, MA, MSc, Paola E Leone, PhD, Brian A Walker, Alison Morilla, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2008) 112 (11): 3136.

https://doi.org/10.1182/blood.V112.11.3136.3136

Published: 2008

Journal Articles

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Sarah L Hockley, PhD, David Gonzalez, PhD, Vasantha Brito-Babapulle, PhD, Monica Else, MA, MSc, Paola E Leone, Brian A Walker, Estella Matutes, MD, PhD, Claire E Dearden, MD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 3140.

https://doi.org/10.1182/blood.V112.11.3140.3140

Published: 2008

Journal Articles

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Monica Else, MA, MSc, Claire E. Dearden, MD, Estella Matutes, MD, Ama Z S Rohatiner, MD, Steve A N Johnson, MD, Nigel T J O’Connor, MD, Andy Haynes, MD, Nnenna Osuji, MD, Daniel Catovsky, MD, DSc(Med)

Blood (2008) 112 (11): 2101.

https://doi.org/10.1182/blood.V112.11.2101.2101

Published: 2008

Journal Articles

The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.

Daniel Catovsky, MD, DSc, Monica Else, MA MSc, Sue Richards, D Phil, Peter Hillmen, MD PhD

Blood (2006) 108 (11): 304.

https://doi.org/10.1182/blood.V108.11.304.304

Published: 2006

NARROW

The Association between Deaths Due to Infection and Mutations of the BRAF, FBXW7, NRAS and XPO1 genes: A Report from the LRF CLL4 Trial

A Distributed International Patient Data Registry for Hairy Cell Leukemia

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only